(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases...
Stats | |
---|---|
今日成交量 | 2.76M |
平均成交量 | 634 418 |
市值 | 135.20M |
EPS | $0 ( 2024-05-02 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.04 |
ATR14 | $0.0960 (14.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Singer Michael | Buy | 178 000 | Common Stock |
2024-01-02 | Singer Michael | Buy | 228 000 | Stock Option (Right to Buy) |
2023-12-22 | Singer Michael | Sell | 3 000 | Series A Convertible Preferred Stock |
2024-01-02 | Davis Blaine | Buy | 3 110 000 | Employee Stock Option (right to buy) |
2024-01-02 | Davis Blaine | Buy | 2 424 000 | Common Stock |
INSIDER POWER |
---|
52.97 |
Last 97 transactions |
Buy: 26 530 299 | Sell: 8 848 103 |
音量 相关性
Selecta Biosciences Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Selecta Biosciences Inc 相关性 - 货币/商品
Selecta Biosciences Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2022 |
营收: | $110.78M |
毛利润: | $38.40M (34.66 %) |
EPS: | $0.240 |
FY | 2021 |
营收: | $85.08M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.220 |
Financial Reports:
No articles found.
Selecta Biosciences Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。